Barclays Increases Tornier N.V. Price Target to $26.00 (TRNX)
Stock analysts at Barclays lifted their target price on shares of Tornier N.V. (NASDAQ:TRNX) from $23.00 to $26.00 in a report issued on Thursday. The firm currently has an “overweight” rating on the stock. Barclays’ target price points to a potential upside of 21.10% from the company’s current price.
Tornier N.V. (NASDAQ:TRNX) traded up 2.00% on Thursday, hitting $21.90. 147,896 shares of the company’s stock traded hands. Tornier N.V. has a one year low of $15.17 and a one year high of $22.44. The stock’s 50-day moving average is $19.75 and its 200-day moving average is $19.17. The company’s market cap is $1.063 billion.
Tornier N.V. (NASDAQ:TRNX) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $89.00 million for the quarter, compared to the consensus estimate of $80.41 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts predict that Tornier N.V. will post $-0.45 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Summer Street upgraded shares of Tornier N.V. from a “sell” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $18.00 price target on the stock, up previously from $16.00. Analysts at Wells Fargo & Co. upgraded shares of Tornier N.V. from a “market perform” rating to an “outperform” rating in a research note on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $20.29.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.